25 recruiting, 11 active not recruiting, 6 withdrawn, 4 completed. 34 Phase 1, 30 Phase 2, 1 Early Phase 1, 1 Phase 3.
Follow ASTX727: new trials by email Literature Review of ASTX727 trials Research Report on ASTX727
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 132 | 2026-11-27 | 2026-09-09 |
| Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 53 | 2026-11-18 | 2026-08-24 |
| Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 126 | 2026-09-25 | 2026-10-21 |
| A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 47 | 2026-06-09 | 2026-10-23 |
| Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Decitabine, Decitabine and Cedazuridine - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | University of Washington | 27 | 2026-03-02 | 2026-08-19 |
| Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes Biospecimen Collection, Bone Marrow Aspiration, Cirtuvivint - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | National Cancer Institute (NCI) | 54 | 2025-08-15 | 2026-10-01 |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 78 | 2025-08-14 | 2026-09-30 |
| Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Myelodysplastic Syndrome | Phase 2 | Recruiting | National Cancer Institute (NCI) | 54 | 2025-06-12 | 2026-10-22 |
| Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 93 | 2025-05-16 | 2026-10-13 |
| Early Intervention in High Risk CCUS Inqovi - Clonal Cytopenia of Undetermined Significance, Cytopenia | Early Phase 1 | Recruiting | Lachelle D. Weeks, MD, PhD | 108 | 2025-02-07 | 2026-04-23 |
| Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms ASTX029, ASTX727 - Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-01-31 | 2026-02-13 | |
| Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib Olutasidenib, Venetoclax, Decitabine - Mutant IDH1 Inhibitor Olutasidenib | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 78 | 2024-08-29 | 2026-10-05 |
| A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation ASTX727, Donor Lymphocyte Infusion - Allogeneic Stem Cell Transplantation | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-07-01 | 2026-05-15 | |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-10-23 |
| ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck INQOVI (decitabine and cedazuridine), Nivolumab - Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma | Phase 1 | Withdrawn | Case Comprehensive Cancer Center | 2024-06-01 | 2024-07-03 | |
| A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) ASTX727, Venetoclax - Acute Myeloid Leukemia | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-03-07 | 2026-09-04 |
| A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia ASTX727, ASTX029-01 - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-02-08 | 2025-03-12 | |
| Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors Olaparib, ASTX727 - BRCA1 Mutation, BRCA2 Mutation | Phase 1 | Active not recruiting | Varun Monga, MBBS | 13 | 2024-02-07 | 2026-10-20 |
| Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Suspended | National Cancer Institute (NCI) | 32 | 2023-09-25 | 2026-07-31 |
| Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 132 | 2023-06-27 | 2026-08-19 |
Showing 20 of 54. Sign in to see all of them.
Leukemia, Myeloid, Acute (26) · Myelodysplastic Syndromes (17) · Leukemia, Myelomonocytic, Chronic (8) · Myeloproliferative Disorders (4) · Anemia, Refractory, with Excess of Blasts (2) · Hodgkin Disease (2) · Lymphoma, Large B-Cell, Diffuse (2) · Myelodysplastic-Myeloproliferative Diseases (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Central Nervous System Neoplasms (1) · Colorectal Neoplasms (1) · Cytopenia (1)
National Cancer Institute (NCI) (14) · M.D. Anderson Cancer Center (13) · Taiho Oncology, Inc. (4) · Astex Pharmaceuticals, Inc. (3) · Case Comprehensive Cancer Center (1) · Clinical Hub for Interventional Research (CHOIR) (1) · Groupe Francophone des Myelodysplasies (1) · Imperial College London (1) · Karyopharm Therapeutics Inc (1) · Kathy Miller (1) · Lachelle D. Weeks, MD, PhD (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · Michael Savona (1)
United States (45) · Spain (6) · Canada (5) · France (5) · Poland (4) · Puerto Rico (4) · Armenia (3) · Australia (3) · Bulgaria (3) · Italy (3) · Romania (3) · Slovakia (3) · United Kingdom (3) · Austria (2) · Germany (2)
Anand A Patel (2) · Courtney DiNardo, MD (2) · Abhishek Maiti (1) · Amber Gibson, DO (1) · Anna Halpern, MD (1) · Betul Oran, MD (1) · Catherine S Diefenbach (1) · Elias Jabbour (1) · Eric J Huselton (1) · Evan C Chen (1) · Farhad Ravandi-Kashani (1) · Farhad Ravandi-Kashani, MD (1) · Gautam Borthakur, MBBS (1) · Ghayas Issa, MD (1) · Guillermo Garcia-Manero (1)
PMID 34552007, PMID 35717027, PMID 35922861, PMID 36902217, PMID 37879695, PMID 38135371, PMID 38316133, PMID 38452788, PMID 39352751, PMID 40513054, PMID 40784355, PMID 41621809, PMID 42013378, PMID 42272166
U10CA180888 (3), UM1CA186689 (3), 2018 (2), U10CA180821 (2), UM1CA186709 (2), P01CA229086 (1), P30CA016087 (1), P50CA097274 (1), R01CA255613 (1), UM1CA186686 (1), UM1CA186717 (1), UM1CA228823 (1)